PTGDS在前列腺癌中的表达及其与AR的相关性研究

陈志贤; 何凯; 黄煜; 曹琪; 阮海龙; 章小平

doi:10.13201/j.issn.1001-1420.2021.05.008

PTGDS在前列腺癌中的表达及其与AR的相关性研究

- 华中科技大学同济医学院附属协和医院泌尿外科(武汉, 430022)
基金项目:
国家自然科学基金(No:82002707)

详细信息

通讯作者: 章小平,E-mail:xzhang@hust.edu.cn

中图分类号: R737.25

收稿日期: 2021-03-02

Expression of PTGDS in prostate cancer and its correlation with AR

- Department of Urology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: ZHANG Xiaoping, E-mail: xzhang@hust.edu.cn

Received Date: 02 March 2021

摘要

摘要: 目的:挖掘前列腺癌进展相关基因并探讨其在前列腺癌中的表达以及与临床参数之间的关系,预测其对前列腺癌进展和预后的影响。方法:通过Oncomine和GEO数据库筛选前列腺癌组织和癌旁组织的测序数据;运用R语言分析数据得到差异表达基因,取交集后筛选出前列腺素D2合成酶(PTGDS);分析其与前列腺癌临床参数以及与雄激素受体(AR)的相关性,通过基因富集分析(GSEA)研究PTGDS在肿瘤中可能的作用和功能。结果:PTGDS在前列腺癌组织中较正常组织呈现相对低表达;免疫组化进一步证实这种表达模式;PTGDS与多种临床参数相关,PTGDS低表达预示更差的预后;GSEA结果提示PTGDS与前列腺癌和AR密切相关,PTGDS表达水平与AR呈明显负相关。结论:PTGDS在前列腺癌中低表达,与前列腺癌的发生发展及多个临床参数相关,且与AR呈负相关,有潜力成为前列腺癌诊断和预后的新的生物标记物。
- 前列腺素D2合成酶 /
- 前列腺癌 /
- 雄激素受体
Abstract: Objective: To explore genes associated with the progression of prostate cancer and their relationships with clinical parameters, and to determine their values in predicting the prognosis of prostate cancer patients.Methods: Oncomine and GEO datasets were used to explore sequencing data about prostate cancer and adjacent normal tissue. R was performed to analyze the data and differentially expressed genes(DEGs) were obtained. We picked PTGDS out of the DEGs and analyzed its association with clinical parameters of prostate cancer and AR. GSEA was performed to reveal the possible roles of PTGDS in the development of prostate cancer.Results: PTGDS showed low expression in prostate cancer compared to normal tissue, which was further validated by immunohistochemical images. PTGDS was associated with many clinical parameters and low expression of PTGDS predicted poor prognosis. GSEA results indicated that PTGDS was closely related to prostate cancer and AR. Also, data from TCGA revealed a significantly negative correlation between PTGDS and AR in prostate cancer.Conclusion: PTGDS was down-regulated in prostate cancer and associated with the progression of prostate cancer and clinical parameters. It was also negatively correlated with AR expression level. It may become a new biomarker for diagnosis and predicting the prognosis of prostate cancer.
- prostaglandin D2 synthase /
- prostate cancer /
- androgen receptor

HTML全文

参考文献(16)

[1]	Bie Q,Li X,Liu S,et al.YAP promotes self-renewal of gastric cancer cells by inhibiting expression of L-PTGDS and PTGDR2[J].Int J Clin Oncol,2020,25(12):2055-2065.
[2]	Zou R,Zheng M,Tan M,et al.Decreased PTGDS Expression Predicting Poor Survival of Endometrial Cancer by Integrating Weighted Gene Co-Expression Network Analysis and Immunohistochemical Validation[J].Cancer Manag Res,2020,12:5057-5075.
[3]	Thompson VC,Day TK,Bianco-Miotto T,et al.A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease[J].Int J Cancer,2012,131(3):662-672.
[4]	Davalieva K,Kiprijanovska S,Maleva Kostovska I,et al.Comparative Proteomics Analysis of Urine Reveals Down-Regulation of Acute Phase Response Signaling and LXR/RXR Activation Pathways in Prostate Cancer[J].Proteomes,2017,6(1):1.
[5]	中国抗癌协会泌尿肿瘤专业委员会.中国去势抵抗性前列腺癌诊治专家共识[J].浙江医学,2016,38(14):1133-1136,1145.
[6]	Culig Z,Santer FR.Androgen receptor signaling in prostate cancer[J].Cancer Metastasis Rev,2014,33(2-3):413-427.
[7]	杨龙雨禾,张贵福,王跃强,等.去势抵抗性前列腺癌治疗进展[J].浙江医学,2020,42(24):2702-2704.
[8]	Weigel N L,Moore N L.Steroid receptor phosphorylation:a key modulator of multiple receptor functions[J].Mol Endocrinol,2007,21(10):2311-2319.
[9]	Kaikkonen S,Jääskeläinen T,Karvonen U,et al.SUMO-specific protease 1(SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells[J].Mol Endocrinol,2009,23(3):292-307.
[10]	Smith WL,Urade Y,Jakobsson PJ.Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis[J].Chem Rev,2011,111(10):5821-5865.
[11]	Kim B H,Kim C I,Chang H S,et al.Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia:is it related to apoptosis and angiogenesis of prostate cancer?[J].Korean J Urol,2011,52(4):253-259.
[12]	Jain S,Chakraborty G,Raja R,et al.Prostaglandin E2 regulates tumor angiogenesis in prostate cancer[J].Cancer Res,2008,68(19):7750-7759.
[13]	Kim J,Yang P,Suraokar M,et al.Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products[J].Cancer Res,2005,65(14):6189-6198.
[14]	Kanaoka Y,Ago H,Inagaki E,et al.Cloning and crystal structure of hematopoietic prostaglandin D synthase[J].Cell,1997,90(6):1085-1095.
[15]	Scher JU,Pillinger MH.15d-PGJ2:the anti-inflammatory prostaglandin?[J].Clin Immunol,2005,114(2):100-109.
[16]	Kaikkonen S,Paakinaho V,Sutinen P,et al.Prostaglandin 15d-PGJ(2) inhibits androgen receptor signaling in prostate cancer cells[J].Mol Endocrinol,2013,27(2):212-223.